BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 15453116)

  • 1. [Amphotericin B: the end of an era].
    Oude Lashof AM; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
    Bellmann R; Cleary JD; Sterba J
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New aspects in treatment of systemic mycoses].
    Presterl E; Graninger W
    Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The current role of amphotericin B lipid complex in managing systemic fungal infections.
    Chu P; Sadullah S
    Curr Med Res Opin; 2009 Dec; 25(12):3011-20. PubMed ID: 19849324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of amphotericin B in the treatment of invasive fungal infections.
    Klepser M
    J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the current and future status of conventional amphotericin B?
    Kleinberg M
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of systemic fungal infections: alternatives to itraconazole.
    Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
    Winston DJ; Schiller GJ
    Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
    [No Abstract]   [Full Text] [Related]  

  • 11. The experience is CLEAR.
    Chandrasekar P
    Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
    Groll AH; Müller FM; Piscitelli SC; Walsh TJ
    Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C; Castagnola E
    Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B: time for a new "gold standard".
    Ostrosky-Zeichner L; Marr KA; Rex JH; Cohen SH
    Clin Infect Dis; 2003 Aug; 37(3):415-25. PubMed ID: 12884167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Amphotericin B: the end of an era].
    Rommes JH; Spronk PE; Saene HK
    Ned Tijdschr Geneeskd; 2005 Jan; 149(2):106; author reply 106-7. PubMed ID: 15688845
    [No Abstract]   [Full Text] [Related]  

  • 16. [Amphotericin B: the end of an era].
    van der Klooster JM; Zandstra DF
    Ned Tijdschr Geneeskd; 2005 Jan; 149(2):107-8; author reply 108. PubMed ID: 15688846
    [No Abstract]   [Full Text] [Related]  

  • 17. Liposomal amphotericin B: what is its role in 2008?
    Lanternier F; Lortholary O
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality rates in comparative trials of formulations of amphotericin B.
    Frothingham R
    Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
    [No Abstract]   [Full Text] [Related]  

  • 20. Injectable amphotericin B: mix-ups between lipid and non-lipid formulations.
    Prescrire Int; 2009 Dec; 18(104):258-60. PubMed ID: 20025095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.